Abstract
The induction of immune tolerance towards self-antigens presents as a viable future strategy in the treatment of auto-immune diseases, including vasculitis and multiple sclerosis (MS). As specific targets are currently lacking for vasculitis due to incomplete understanding of the pathologies underlying this disease, current treatment options are based on modalities that induce general immune suppression. However, many immune suppressants used in the clinic are known to display wide biodistribution and are thus often accompanied by several adverse effects. Nano-vehicles (NVs) possess the ability to overcome such limitations by enabling more specific delivery of their content through modifications with targeting moieties. In this review, we describe the latest insights in the pathology of vasculitis that may function as potential targets for NV carrier systems, allowing more specific delivery of currently used immune suppressants. In addition, we describe the existing strategies to induce artificial immune tolerance and explore the feasibility of inducing regulatory T cell (Treg) mediated tolerance for MS, possibly mediated by NVs.
Keywords: Nano-vehicle, nanoparticle, vasculitis, multiple sclerosis, drug delivery, targeting, drug release, immune suppressive drugs, nanomedicine, glucocorticosteroids.
Current Pharmaceutical Design
Title:The Potential of Nano-Vehicle Mediated Therapy in Vasculitis and Multiple Sclerosis
Volume: 23 Issue: 13
Author(s): R. Huis In ’t Veld, C.G. Da Silva, E.L. Kaijzel, A.B. Chan and L.J. Cruz*
Affiliation:
- Translational Nanobiomaterials and Imaging, Department of Radiology, Leiden University Medical Center, Leiden,Netherlands
Keywords: Nano-vehicle, nanoparticle, vasculitis, multiple sclerosis, drug delivery, targeting, drug release, immune suppressive drugs, nanomedicine, glucocorticosteroids.
Abstract: The induction of immune tolerance towards self-antigens presents as a viable future strategy in the treatment of auto-immune diseases, including vasculitis and multiple sclerosis (MS). As specific targets are currently lacking for vasculitis due to incomplete understanding of the pathologies underlying this disease, current treatment options are based on modalities that induce general immune suppression. However, many immune suppressants used in the clinic are known to display wide biodistribution and are thus often accompanied by several adverse effects. Nano-vehicles (NVs) possess the ability to overcome such limitations by enabling more specific delivery of their content through modifications with targeting moieties. In this review, we describe the latest insights in the pathology of vasculitis that may function as potential targets for NV carrier systems, allowing more specific delivery of currently used immune suppressants. In addition, we describe the existing strategies to induce artificial immune tolerance and explore the feasibility of inducing regulatory T cell (Treg) mediated tolerance for MS, possibly mediated by NVs.
Export Options
About this article
Cite this article as:
In ’t Veld Huis R. , Silva Da C.G. , Kaijzel E.L. , Chan A.B. and Cruz L.J. *, The Potential of Nano-Vehicle Mediated Therapy in Vasculitis and Multiple Sclerosis, Current Pharmaceutical Design 2017; 23 (13) . https://dx.doi.org/10.2174/1381612822666161221151900
DOI https://dx.doi.org/10.2174/1381612822666161221151900 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pentraxin 3 Serum Levels in Celiac Patients: Evidences and Perspectives
Recent Patents on Food, Nutrition & Agriculture Editorial [Hot Topic:Anti-Inflammatory Strategy: Old Ally or New Promise in Therapy (Guest Editor: Marcella Reale)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Pathobiology of Stent Thrombosis after Drug-Eluting Stent Implantation
Current Pharmaceutical Design Myopericarditis, as the First Sign of Rheumatoid Arthritis Relapse, Evaluated by Cardiac Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Alterations in the Vascular Reactivity of Aorta in the Early and Late Phase of Adjuvant-Induced Arthritis in Rat
Vascular Disease Prevention (Discontinued) Role of Alpha-1 Antitrypsin (AAT) in Ocular Allergy and Uveitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy
Current Pharmaceutical Design Rheumatological Manifestations in Diabetes Mellitus
Current Diabetes Reviews Pentoxifylline Use in Dermatology
Inflammation & Allergy - Drug Targets (Discontinued) Vascular Inflammation During Human Rickettsioses: An Essential Host Response and a Potential Target for Supplemental Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews Multimodalities Imaging of Immunoglobulin 4-related Cardiovascular Disorders
Current Cardiology Reviews Editorial [Hot Topic: Cardiovascular Risk and Inflammation: Pathophysiological Mechanisms, Drug Design, and Targets Executive (Guest Editor: Armen Yuri Gasparyan)]
Current Pharmaceutical Design Unusual Cerebral Involvement of Rheumatoid Arthritis Mimicking a Tumor
Current Medical Imaging Remote Preconditioning- Endocrine Factors in Organ Protection Against Ischemic Injury
Endocrine, Metabolic & Immune Disorders - Drug Targets Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial
Current Rheumatology Reviews Modulation of Eosinophil Functions by Nitric Oxide: Cyclic GMPdependent and -independent Mechanisms
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 123I-FP-CIT Brain SPECT Findings in Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency
Current Radiopharmaceuticals Cigarette Smoking and Angiogenesis: What is the Role of Endothelial Progenitor Cells?
Current Angiogenesis (Discontinued)